Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 51 results for copd exacerbation

  1. Cough (acute): antimicrobial prescribing (NG120)

    This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    7 February 2019
    View recommendations

    Sections for NG120

  2. What is the impact and longer-term clinical outcomes of adding procalcitonin testing to standard clinical practice with protocol-driven care in the NHS, to guide the use of antibiotic treatment in adults presenting to the emergency department with exacerbations of chronic inflammatory respiratory conditions such as chronic obstructive pulmonary disease?

    emergency department with exacerbations of chronic inflammatory respiratory conditions such as chronic obstructive pulmonary...

    Research recommendation
    Published
    12 January 2016

  3. Evidence on the safety and efficacy of endobronchial nerve ablation for chronic obstructive pulmonary disease (COPD) is inadequate in quantity. Therefore, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page. Further research should be randomised controlled trials comparing the procedure with sham treatment. It should report details of patient selection, and short and long-term functional outcomes including lung functional outcomes, quality of life and patient-reported outcomes, incidence of exacerbations and hospital admissions, and all adverse events.

    safety and efficacy of endobronchial nerve ablation for chronic obstructive pulmonary disease (COPD) is inadequate in...

    Research recommendation
    Published
    7 January 2022

  4. O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)

    NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .

    Medtech innovation briefing
    Published
    11 October 2022

  5. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (DG18)

    Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay)

    Diagnostics guidance
    Published
    7 October 2015

    Sections for DG18

  6. myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)

    NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .

    Medtech innovation briefing
    Published
    1 October 2018

  7. Further good quality evidence is needed to address uncertainties about myCOPD's clinical benefits and its effect on healthcare resource use. myCOPD has potential for clinical benefits, but more evidence is needed to reduce uncertainties. The committee considered that comparative evidence is needed to show the clinical benefits of using myCOPD in 2 populations: people using it to self-manage COPD people referred to pulmonary rehabilitation For self-management, a randomised controlled trial is preferred to show the clinical benefits of myCOPD. This could be powered based on the encouraging results in the RESCUE study. However, a high-quality comparative observational study designed to minimise bias in the results may provide acceptable evidence. Outcomes such as rates of exacerbations, hospital readmissions and unscheduled care appointments should be considered alongside patient-reported outcomes such as health-related quality of life. For pulmonary rehabilitation, further evidence is needed to show the clinical benefits of myCOPD. This could be a randomised controlled trial which is powered based on the encouraging results in the TROOPER study or a well-designed comparative observational study. Key outcomes will be the CAT score and 6-minute walk test, ideally supported by additional longer-term outcomes such as rates of exacerbations and hospital admissions. Real-world data could be used to inform the uptake rates in the economic modelling. It should also include qualitative data on patient experience using myCOPD such as patient preferences and adherence.

    benefits of using myCOPD in 2 populations: people using it to self-manage COPD people referred to pulmonary rehabilitation For...

    Research recommendation
    Published
    8 April 2022

  8. Smart One for measuring lung function (MIB96)

    NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .

    Medtech innovation briefing
    Published
    9 February 2017

  9. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

    Technology appraisal guidance
    Published
    25 February 2009
    View recommendations

    Sections for TA168

  10. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (IPG677)

    Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. This involves delivering electrical impulses to weakened muscles using electrodes placed on the skin.

    Interventional procedures guidance
    Published
    5 August 2020
    View recommendations

    Sections for IPG677

  11. Research recommendations

    service users' experience and adverse events (for example, distress or exacerbation of symptoms associated with therapy) should be...

  12. Bronchoscopic thermal vapour ablation for upper-lobe emphysema (IPG652)

    Evidence-based recommendations on bronchoscopic thermal vapour ablation for upper-lobe emphysema in adults. This involves using steam to destroy the diseased part of the lung.

    Interventional procedures guidance
    Published
    12 June 2019
    View recommendations

    Sections for IPG652

  13. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  14. Extracorporeal carbon dioxide removal for acute respiratory failure (IPG776)

    Evidence-based recommendations on extracorporeal carbon dioxide removal for acute respiratory failure. This involves taking blood out of the circulatory system and passing it across a synthetic membrane that allows some of the carbon dioxide in the blood to be removed. The blood is then returned to the circulatory system.

    Interventional procedures guidance
    Published
    15 November 2023
    View recommendations

    Sections for IPG776

  15. Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis (CG95)

    This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.

    Clinical guideline
    Last updated
    30 November 2016
    View recommendations

    Sections for CG95